Data suggested that tumor-associated macrophages (TAMs) in the SphK2-deficient tumors displayed a pronounced antitumor phenotype, with an increased expression of proinflammatory markers/mediators such as NO, TNFα, IL-12, and MHCII and a low expression of anti-inflammatory IL-10 and CD206 [111]. This evidence concerns the gene SPHK2 and neoplasm.